{"id":"mycophenolate-mofetil-or-azathioprine","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Leukopenia"},{"rate":"5-10%","effect":"Anemia"},{"rate":"1-5%","effect":"Thrombocytopenia"},{"rate":"1-5%","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting IMPDH, these drugs reduce the production of guanosine nucleotides, which are essential for the proliferation of lymphocytes. This action suppresses the immune system, making it less likely to reject transplanted organs. Additionally, by reducing the number of lymphocytes, these drugs also decrease the production of antibodies, which can contribute to inflammation and tissue damage.","oneSentence":"Mycophenolate mofetil and azathioprine are immunosuppressive drugs that inhibit the enzyme inosine monophosphate dehydrogenase (IMPDH), which is necessary for the proliferation of T and B lymphocytes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:21.365Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in patients with kidney, liver, or heart transplants"},{"name":"Treatment of certain autoimmune diseases, such as lupus nephritis and myasthenia gravis"}]},"trialDetails":[{"nctId":"NCT07290803","phase":"","title":"This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-11-17","conditions":"Atopic Dermatitis","enrollment":1000},{"nctId":"NCT02081755","phase":"PHASE4","title":"Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Baylor Research Institute","startDate":"2014-03","conditions":"Carcinoma, Hepatocellular","enrollment":336},{"nctId":"NCT04745728","phase":"PHASE3","title":"Different Immunosuppressive Treatment in iMN","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-04-14","conditions":"Idiopathic Membranous Nephropathy","enrollment":200},{"nctId":"NCT04773392","phase":"PHASE4","title":"Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2021-11-23","conditions":"Kidney Transplantation, Kidney Transplant Rejection","enrollment":20},{"nctId":"NCT01284725","phase":"PHASE3","title":"Weaning of Immunosuppression in Nephritis of Lupus","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2011-02-16","conditions":"Nephritis of Lupus","enrollment":100},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT05237323","phase":"PHASE3","title":"Micophenolate Mofetil Versus Azathioprine in Myocarditis","status":"COMPLETED","sponsor":"I.M. Sechenov First Moscow State Medical University","startDate":"2020-10-01","conditions":"Lymphocytic Myocarditis (Disorder), Heart Failure, Dilated Cardiomyopathy","enrollment":50},{"nctId":"NCT03828019","phase":"PHASE3","title":"Adalimumab vs. Conventional Immunosuppression for Uveitis Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2019-09-16","conditions":"Uveitis","enrollment":227},{"nctId":"NCT05998759","phase":"PHASE2","title":"Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2023-12-02","conditions":"Connective Tissue Diseases, Thrombocytopenia","enrollment":296},{"nctId":"NCT06763848","phase":"NA","title":"Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder","status":"RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2025-04-25","conditions":"Neuromyelitis Optica Spectrum Disorders","enrollment":144},{"nctId":"NCT05060991","phase":"PHASE4","title":"Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2021-09-24","conditions":"COVID-19, Immunosuppression, Vaccine Response Impaired","enrollment":50},{"nctId":"NCT04469842","phase":"EARLY_PHASE1","title":"Early Use of Long-acting Tacrolimus in Lung Transplant Recipients","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-12-01","conditions":"Lung Transplant; Complications","enrollment":48},{"nctId":"NCT04871191","phase":"PHASE3","title":"Study of Salvage Therapy to Treat Patients with Granulomatosis with Polyangiitis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-03","conditions":"Granulomatosis with Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis","enrollment":42},{"nctId":"NCT04660539","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-03-02","conditions":"Neuromyelitis Optica Spectrum Disorder","enrollment":119},{"nctId":"NCT06155604","phase":"PHASE2","title":"SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2023-01-04","conditions":"Lupus Nephritis, Chronic Kidney Diseases","enrollment":150},{"nctId":"NCT05891379","phase":"","title":"Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-07-09","conditions":"Neuromyelitis Optica Spectrum Disorder","enrollment":50},{"nctId":"NCT00103792","phase":"PHASE3","title":"Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2004-12","conditions":"Wegener's Granulomatosis, Vasculitis","enrollment":84},{"nctId":"NCT02426502","phase":"NA","title":"Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of British Columbia","startDate":"2016-04","conditions":"End-Stage Renal Disease","enrollment":76},{"nctId":"NCT02498977","phase":"PHASE4","title":"Liver Immunosuppression Free Trial","status":"TERMINATED","sponsor":"King's College London","startDate":"2015-10","conditions":"Transplantation, Liver","enrollment":116},{"nctId":"NCT05458531","phase":"","title":"Monitoring of Inflammatory Conditions","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2022-06-28","conditions":"Inflammatory Disease, Crohn Disease, Ulcerative Colitis","enrollment":664},{"nctId":"NCT05247203","phase":"PHASE1","title":"Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2022-05-11","conditions":"Systemic Lupus Erythematosus","enrollment":92},{"nctId":"NCT03871361","phase":"PHASE2","title":"Abatacept in Patients With Birdshot HLA A29 Uveitis","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2019-04-01","conditions":"Eye Diseases, Uveitis","enrollment":15},{"nctId":"NCT05263505","phase":"PHASE2","title":"Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2022-02-21","conditions":"Mucous Membrane Pemphigoid, Cicatrizing Conjunctivitis","enrollment":2},{"nctId":"NCT04082416","phase":"PHASE3","title":"Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2019-10-16","conditions":"Systemic Lupus Erythematosus","enrollment":335},{"nctId":"NCT02028884","phase":"PHASE3","title":"Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-02-20","conditions":"Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)","enrollment":85},{"nctId":"NCT05415579","phase":"","title":"Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM)","status":"NOT_YET_RECRUITING","sponsor":"Dongzhimen Hospital, Beijing","startDate":"2022-06-20","conditions":"Demyelinating Diseases of the Central Nervous System (DDC)","enrollment":2000},{"nctId":"NCT05338177","phase":"PHASE1","title":"Pilot Trial on Immunosuppression Modulation to Increase SARS-CoV-2 Vaccine Response in Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2021-11-15","conditions":"COVID-19","enrollment":40},{"nctId":"NCT04124861","phase":"NA","title":"Withdraw Drug in Stable IgG4-Related Disease","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-06-23","conditions":"Autoimmune Diseases","enrollment":138},{"nctId":"NCT02015351","phase":"NA","title":"Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2012-09","conditions":"Choroidal Neovascularization","enrollment":9},{"nctId":"NCT05078294","phase":"","title":"Results in Real Clinical Practice of Treatment of Moderate-severe Atopic Dermatitis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2021-08-01","conditions":"Dermatitis, Atopic","enrollment":300},{"nctId":"NCT03412188","phase":"NA","title":"The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP.","status":"COMPLETED","sponsor":"Nayera Hazaa Elsherif","startDate":"2018-08-01","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":36},{"nctId":"NCT05095103","phase":"","title":"Immune Profiles in Myasthenia Gravis","status":"UNKNOWN","sponsor":"University of Manchester","startDate":"2021-10","conditions":"Myasthenia Gravis","enrollment":163},{"nctId":"NCT04101578","phase":"","title":"Clinical Prognosis and Progression of Myasthenia Gravis Patients","status":"UNKNOWN","sponsor":"Da, Yuwei, M.D.","startDate":"2017-02-08","conditions":"Myasthenia Gravis","enrollment":2000},{"nctId":"NCT01639339","phase":"PHASE3","title":"Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2012-07-12","conditions":"Lupus Nephritis","enrollment":448},{"nctId":"NCT00626197","phase":"PHASE3","title":"A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2008-02-15","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus","enrollment":381},{"nctId":"NCT00539838","phase":"PHASE3","title":"A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2007-12-19","conditions":"Systemic Lupus Erythematosus","enrollment":33},{"nctId":"NCT02349061","phase":"PHASE2","title":"A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-15","conditions":"Lupus Erythematosus, Systemic","enrollment":102},{"nctId":"NCT02885610","phase":"PHASE2","title":"Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2015-12","conditions":"Systemic Lupus Erythematosus","enrollment":249},{"nctId":"NCT02723786","phase":"PHASE2","title":"Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal Transplantation","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2016-08-27","conditions":"Kidney Transplantation (Status Post)","enrollment":7},{"nctId":"NCT03791827","phase":"","title":"Multicenter Registry of Pediatric Lupus Nephritis in China","status":"UNKNOWN","sponsor":"Xiqiang Dang","startDate":"2018-12-01","conditions":"Lupus Nephritis, Children, Steroid","enrollment":1200},{"nctId":"NCT03886233","phase":"","title":"Treatment Outcome of Uveitis in Autoimmune Diseases","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-03","conditions":"Autoimmune Uveitis","enrollment":1},{"nctId":"NCT01433978","phase":"PHASE3","title":"A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2012-03-26","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":24},{"nctId":"NCT01438840","phase":"PHASE3","title":"Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2012-02-16","conditions":"Chronic Thrombocytopenia, Immune Thrombocytopenia","enrollment":49},{"nctId":"NCT00494741","phase":"PHASE4","title":"MMF vs. AZA for Kidney Transplantation","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2007-05","conditions":"Kidney Transplant","enrollment":233},{"nctId":"NCT01797315","phase":"PHASE4","title":"Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol","status":"TERMINATED","sponsor":"University Hospital of Berlin","startDate":"2007-03","conditions":"Renal Transplant Patients at High-risk for Skin Cancer","enrollment":40},{"nctId":"NCT01275274","phase":"PHASE2","title":"Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens","status":"WITHDRAWN","sponsor":"University of North Carolina, Chapel Hill","startDate":"2012-01","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","enrollment":""},{"nctId":"NCT02671318","phase":"PHASE4","title":"Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence","status":"UNKNOWN","sponsor":"Hospital do Rim e Hipertensão","startDate":"2015-09","conditions":"Cytomegalovirus Infections","enrollment":250},{"nctId":"NCT01834157","phase":"","title":"Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis","status":"UNKNOWN","sponsor":"Prof. Laszlo Czirjak","startDate":"2013-04","conditions":"Systemic Sclerosis, Arthritis","enrollment":160},{"nctId":"NCT00425438","phase":"PHASE3","title":"A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-03","conditions":"Lupus Nephritis","enrollment":52},{"nctId":"NCT01914770","phase":"","title":"Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Systemic Lupus Erythematosus","enrollment":1016},{"nctId":"NCT00768729","phase":"PHASE1","title":"Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-05","conditions":"Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression","enrollment":7},{"nctId":"NCT00447265","phase":"PHASE2","title":"Etanercept for the Treatment of Lupus Nephritis","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-02","conditions":"Lupus Nephritis","enrollment":1},{"nctId":"NCT00230035","phase":"PHASE2","title":"Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-09","conditions":"Systemic Lupus Erythematosus","enrollment":""},{"nctId":"NCT01613963","phase":"","title":"Causes of Visual Loss in Retinal Disease","status":"UNKNOWN","sponsor":"Royal Surrey County Hospital NHS Foundation Trust","startDate":"2012-05","conditions":"Uveitis, Scleritis","enrollment":2000},{"nctId":"NCT01213394","phase":"PHASE3","title":"Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients","status":"TERMINATED","sponsor":"Ramesh Prasad","startDate":"2010-10","conditions":"Kidney Transplantation, Cardiovascular Diseases","enrollment":2},{"nctId":"NCT00377637","phase":"PHASE3","title":"A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-07","conditions":"Lupus Nephritis","enrollment":370},{"nctId":"NCT00307671","phase":"PHASE4","title":"Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2005-07","conditions":"Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis","enrollment":108},{"nctId":"NCT00695344","phase":"PHASE4","title":"Study to Evaluate Effect of Everolimus in Progression of Graft Vascular Illness on Patients With Heart Transplant","status":"UNKNOWN","sponsor":"Fundacion Investigacion y Desarrollo","startDate":"2006-01","conditions":"Cardiac Transplant","enrollment":52},{"nctId":"NCT00753103","phase":"PHASE2","title":"Anti-Cytokine Therapy for Vasculitis","status":"COMPLETED","sponsor":"University Hospital Birmingham NHS Foundation Trust","startDate":"2003-01","conditions":"Wegener's Granulomatosis, Renal Limited Vasculitis, Microscopic Polyangiitis","enrollment":37},{"nctId":"NCT00431119","phase":"PHASE2","title":"Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid","status":"COMPLETED","sponsor":"University Hospital Muenster","startDate":"1997-10","conditions":"Bullous Pemphigoid","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"mycophenolate mofetil or azathioprine","genericName":"mycophenolate mofetil or azathioprine","companyName":"Assistance Publique Hopitaux De Marseille","companyId":"assistance-publique-hopitaux-de-marseille","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mycophenolate mofetil and azathioprine are immunosuppressive drugs that inhibit the enzyme inosine monophosphate dehydrogenase (IMPDH), which is necessary for the proliferation of T and B lymphocytes. Used for Prevention of organ rejection in patients with kidney, liver, or heart transplants, Treatment of certain autoimmune diseases, such as lupus nephritis and myasthenia gravis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}